Company intelligence / Profile preview
Neuronascent
Clarksville, Maryland, USAneuronascent.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Neuronascent has developed a proprietary small molecule-based platform to promote adult neurogenesis and neuronal survival. Their lead candidate, NNI‑362, has completed Phase 1a trials demonstrating safety in healthy aged subjects. The company aims to advance into patient studies for mild-to-moderate Alzheimer’s disease and early Parkinson's disease. Preclinical data show efficacy in animal models of chronic neurodegenerative diseases, with the potential to reverse or halt progression by regenerating functional neurons.
- Therapeutic areas
- PsychiatryNeurology
- Modalities
- Small molecule
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
Request access →03
Partnerships
ChemRar Pharma – collaboration on screening developmental pathway inhibitors using Neuronascent’s neurogenesis platform for co-development opportunities.
Beyond the preview
Go deeper on Neuronascent.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Neuronascent.